Concert Pharma (CNCE) Announces Results of CTP-656 Phase 1; Demonstrated Superior PK Profile to Kalydeco
Tweet Send to a Friend
Concert Pharma (NASDAQ: CNCE) announced positive data from a Phase 1 single ascending dose clinical trial of CTP-656. CTP-656 is ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
